MISSISSAUGA, Ontario, March 8, 2011 /PRNewswire/ — CardioGenics
Holdings Inc. (OTC Bulletin Board:
CGNH) announced today that it is making available to its common
stockholders and Series 2 Class B common stockholders a
“Stockholder Questionnaire,” which the Company hopes will assist it
in obtaining an accurate share count of the Company’s shares
currently held in “street name” through brokers, banks or
other nominees.
If you have not received the Stockholder Questionnaires via
mail, you can download copies of the questionnaires from the
“Investor Relations” section of the Company’s website (www.cardiogenics.com). We
urge all stockholders to take the time to complete and return the
applicable questionnaire to the Company as soon as possible. The
questionnaires contain the mailing address, fax number and e-mail
address, which can be used by stockholders for returning their
completed questionnaires.
Any inquiries regarding the questionnaires can be directed to
Creative Capital and Trading, Inc., which is assisting the Company
in this matter:
Creative Capital and Trading, Inc.
Attention: Tony Forte – Tel: 732-751-1947 or
Jeff Goss – Tel: 732-556-6924
About CardioGenics Holdings Inc.
Through its operating subsidiaries, the Company develops
ultra-sensitive analyzers and other products targeting the
immunoassay segment of the Point-Of-Care IVD testing market. It has
developed the QL Care™ Analyzer, a proprietary and
ultra-sensitive Point-Of-Care immuno-analyzer, which will run a
number of diagnostic tests under development, the first of which
will be a series of cardiovascular diagnostic tests. As part of its
core proprietary technology, the Company has also developed a
proprietary method for silver coating paramagnetic microspheres (a
fundamental pla
‘/>”/>
SOURCE